CYP2C19 and acute coronary syndrome: Another research on the cost-effectiveness of CYP2C19 genotype-guided antiplatelet treatment in Korean patients having PCI for acute coronary syndrome found that adding genotyping into clinical decision-making was a cost-effective strategy that resulted in improved clinical outcomes and decreased healthcare costs when compared to standard therapy.